Trends & Forecasts

Can pharma get over its IP anxiety and embrace meaningful partnerships?

If pharma is to retain its reputation as an innovator, companies must be brave enough to explore new areas, new targets and new technologies.

Sitting Down With… Andy Skibo, Executive Vice President, Operations at MedImmune, and Chairman of the ISPE.

Big pharma must be more agile if it wants to make the most of the revolutionary advances that will shape the next decade.

Who should pay for the disposal of unused medicines? Legal tussles continue over ‘drug takeback’ law in Californian county.

Who are the top 100 most influential people in drug development and manufacturing today?

Science and business: tenacious partners in a shaky marriage or eternally bound nonidentical twins?

How to use a knowledge repository that doesn’t retire or leave you for a competitor.

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The 2014 Access to Medicine index shows progress – but companies remain “conservative”